[1]孟凡萍,郝 坡.渝东北地区441 例白血病患者融合基因表达特点分析[J].现代检验医学杂志,2020,35(02):15-17.[doi:10.3969/j.issn.1671-7414.2020.02.005]
 MENG Fan-ping,HAO Po.Analysis of Expression Characteristics of Fusion Gene in 441 Patientswith Leukemia in Northeastern Chongqing[J].Journal of Modern Laboratory Medicine,2020,35(02):15-17.[doi:10.3969/j.issn.1671-7414.2020.02.005]
点击复制

渝东北地区441 例白血病患者融合基因表达特点分析()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年02期
页码:
15-17
栏目:
论 著
出版日期:
2020-05-24

文章信息/Info

Title:
Analysis of Expression Characteristics of Fusion Gene in 441 Patientswith Leukemia in Northeastern Chongqing
文章编号:
1671-7414(2020)02-015-03
作者:
孟凡萍1郝 坡2
(1. 重庆三峡中心医院, 重庆404000;2. 重庆三峡医药高等专科学校, 重庆400020)
Author(s):
MENG Fan-ping1HAO Po2
(1.Chongqing Three Gorges Central Hospital,Chongqing 404000, China ;2. Chongqing Three Gorges MedicalCollege,Chongqing 404020, China)
关键词:
白血病融合基因实时荧光定量逆转录PCR白血病微小残留病变BCR-ABL
分类号:
R557;Q786
DOI:
10.3969/j.issn.1671-7414.2020.02.005
文献标志码:
A
摘要:
目的 探讨渝东北地区白血病患者融合基因表达特点。方法选取2017 年1 月~ 2019 年9 月期间于重庆三峡中心医院就诊的白血病患者441 例,用实时荧光定量逆转录- 聚合酶链反应(FQ-RT-PCR)法检测其43 种白血病融合基因的表达情况。结果 441 例患者中,检出193 例患者有融合基因表达,其中BCR/ABL 为75.13%(145/193),AMLETO为8.29%(16/193),PML-RARa 为6.22%(12/193),MLL-AF9 为4.15%(8/193),CBF β-MYH11 为2.59%(5/193),MLL-AF4 ,WT1 和E2A-PBX1 均为0.52%(1/193);MLL-AF6,MLL-AF10,ELL,ENL 联合阳性率为1.55%(3/193),WT1 和PML-RARa 联合阳性率0.52%(1/193),其余基因未检出。结论 融合基因的表达在白血病的诊断和疗效评估中起重要作用。

参考文献/References:

[1] ARBER D A, ORAZI A, HASSERJIAN R, et al.The 2016 revision to the World Health Organizationclassification of myeloid neoplasms and acuteleukemia[J]. Blood, 2016, 127(20): 2391-2405.
[2] DE BRAEKELEER E, DOUET-GUILBERT N, DEBRAEKELEER M. RARA fusion genes in acutepromyelocytic leukemia: a review[J]. Expert Review ofHematology, 2014, 7(3): 347-357.
[3] WANG Xinrui, FAN Huiyong, XU Congling, et al.KDM3B suppresses APL progression by restrictingchromatin accessibility and facilitating the ATRAmediateddegradation of PML/RARα[J] .Cancer CellInternational, 2019,19(1): 256.
[4] YE Jing, ZHA Jie, SHI Yuanfei, et al. Co-inhibitionof HDAC and MLL-menin interaction targets MLLrearrangedacute myeloid leukemia cells via disruptionof DNA damage checkpoint and DNA repair[J].Clinical Epigenetics, 2019, 11(1): 137.
[5] TOMLINSON B, LAZARUS H M. Enhancing acutemyeloid leukemia therapy - monitoring responseusing residual disease testing as a guide to therapeuticdecision-making[J]. Expert Review of Hematology,2017, 10(6): 563-574.
[6] TONG Yongqing, ZHAO Zhijun, LIU Bei, et al. Newrapid method to detect BCR-ABL fusion genes withmultiplex RT-qPCR in one-tube at a time[J]. LeukemiaResearch, 2018, 69: 47-53.
[7] WANG Ziwei, GUO Mengqiao, ZHANG Yuesheng, etal. The applicability of multiparameter flow cytometryfor the detection of minimal residual disease usingdifferent-from-normal panels to predict relapse inpatients with acute myeloidleukemia after allogeneictransplantation[J]. International Journal of LaboratoryHematology, 2019, 41(5): 607-614.
[8] HRABOVSKY S, FOLBER F, HORACEK J M, etal. Comparison of real-time quantitative polymerasechain reaction and eight-color flow cytometry inassessment of minimal residual disease in adult acutelymphoblastic leukemia[J]. Clinical LymphomaMyeloma & Leukemia, 2018, 18(11): 743-748.
[9] 张坤龙,王宁玲,徐修才,等.多重RT-PCR 检测儿童急性淋巴细胞白血病融合基因的临床研究[J].中国小儿血液与肿瘤杂志,2014,19(5):233-237.   ZHANG Kunlong,WANG Ningling,XU Xiucai,et al. The clinical study on fusion genes in childhoodacute lymphoblastic leukemia by multiplex ;RT-PCR[J].Journal of China Pediatric Blood and Cancer,2014,19(5):233-237.
[10] L VVIK JUUL-DAM K,GULDBORG NYVOLD C, VALERHAUGEN H, et al.Measurable residual diseasemonitoring using Wilms tumor gene 1 expression inchildhood acute myeloid leukemia based on childspecificreference values[J].Pediatr Blood Cancer,2019 ,66(6):e27671.
[11] SELIM A G, MOORE A S. Molecular minimalresidual disease monitoring in acute myeloid leukemiachallenges and future directions[J]. Journal ofMolecular Diagnostics, 2018, 20(4): 389-397.
[12] SINGH M, BHATIA P, TREHAN A,et al. High frequencyof intermediate and poor risk copy numberabnormalities in pediatric cohort of B-ALL correlatewith high MRD post induction. [J]. Leuk Res,2018 ,66:79-84.

相似文献/References:

[1]苗玉迪a,魏绪仓b.达沙替尼联合氟达拉滨对慢粒K562细胞的抑制作用研究[J].现代检验医学杂志,2015,30(05):70.[doi:10.3969/j.issn.1671-7414.2015.05.021]
 MIAO Yu-dia,WEI Xu-cangb.Study on Inhibition of Dasatinib and Fludarabine to CML K562 Cells[J].Journal of Modern Laboratory Medicine,2015,30(02):70.[doi:10.3969/j.issn.1671-7414.2015.05.021]
[2]姚亚洲,郑引索.72例老年急性白血病免疫表型分析[J].现代检验医学杂志,2015,30(05):91.[doi:10.3969/j.issn.1671-7414.2015.05.027]
 YAO Ya-zhou,ZHENG Yin-suo.Immunophenotype Analysis of 72 Cases of Elderly Acute Leukemia[J].Journal of Modern Laboratory Medicine,2015,30(02):91.[doi:10.3969/j.issn.1671-7414.2015.05.027]
[3]王结珍,梁培松,王伟佳,等.血清PCT,IL-6和CRP水平检测对白血病患者化疗并发败血症的诊断价值[J].现代检验医学杂志,2019,34(02):88.[doi:10.3969/j.issn.1671-7414.2019.02.023]
 WANG Jie-zhen,LIANG Pei-song,WANG Wei-jia,et al.Diagnostic Value of Serum PCT,IL-6 and CRPin Septicemia Patients with Leukemia in Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(02):88.[doi:10.3969/j.issn.1671-7414.2019.02.023]
[4]付朝泓,李艳,童永清,等.BCR-ABL融合基因核酸检测试剂的研发及临床应用[J].现代检验医学杂志,2015,30(06):52.[doi:10.3969/j.issn.1671-7414.2015.06.015]
 FU Chao-hong,LI Yan,TONG Yong-qing,et al.Development and Clinical Application of A Novel Nucleic Acid Detection Reagent for BCR-ABL Fusion Gene[J].Journal of Modern Laboratory Medicine,2015,30(02):52.[doi:10.3969/j.issn.1671-7414.2015.06.015]

备注/Memo

备注/Memo:
基金项目: 重庆市自然科学基金面上项目(重庆市科技局,cstc2019jcyj-msxmX0122)。作者简介: 孟凡萍(1980-),女,医学博士,副主任检验师,研究方向:脂代谢和胰岛素抵抗,E-mail:63405353@qq.com。通讯作者: 郝坡(1979-),男,医学硕士,副教授,研究方向:肿瘤分子生物学检验,E-mail:hpo1979@126.com。收稿日期:2019-10-13修回日期:2019-11-29
更新日期/Last Update: 2020-04-30